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Abstract 
Aldosterone produces a multitude of effects in vivo, including promotion of post-myocardial 
infarction adverse cardiac remodeling and heart failure progression. It is produced and secreted 
by the adrenocortical zona glomerulosa (AZG) cells after angiotensin II (AngII) activation of 
AngII type 1 receptors (AT1Rs). Up until now, the general consensus for AngII signaling to 
aldosterone production has been that it proceeds via activation of Gq/11-proteins, to which the 
AT1R normally couples.  Here, we describe a novel signaling pathway underlying this AT1R-
dependent aldosterone production mediated by β−arrestin (βarr) -1, a universal heptahelical 
receptor adapter/scaffolding protein. This pathway results in sustained extracellular signal-
regulated kinase (ERK) activation and subsequent upregulation of StAR, a steroid transport 
protein regulating aldosterone biosynthesis in AZG cells. In addition, this βarr1-mediated 
pathway appears capable of promoting aldosterone turnover independently of G-protein 
activation, since treatment of AZG cells with SII, an AngII analog that induces βarr, but not G-
protein coupling to the AT1R, recapitulates the effects of AngII on aldosterone production and 
secretion. In vivo, increased adrenal βarr1 activity, by means of adrenal-targeted adenoviral-
mediated gene delivery of a βarr1 transgene, resulted in a marked elevation of circulating 
aldosterone levels in otherwise normal animals, suggesting that this adrenocortical βarr1-
mediated signaling pathway is operative, and promotes aldosterone production and secretion in 
vivo, as well. Thus, inhibition of adrenal βarr1 activity on AT1Rs might be of therapeutic value 
in pathological conditions characterized and aggravated by hyperaldosteronism. 
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\body              
Aldosterone is one of a number of hormones that can be detrimental to myocardium, and whose 
circulating levels are elevated in chronic heart failure (HF).  It contributes significantly to HF 
progression after myocardial infarction (MI) and to the morbidity and mortality of the disease (1-
3).  Aldosterone`s main actions on the post-MI heart include (but are not limited to) cardiac 
hypertrophy, fibrosis, and increased inflammation and oxidative stress, all of which result in 
adverse cardiac remodeling and progressive loss of cardiac function and performance (2-4).   
 Aldosterone is a mineralocorticoid produced and secreted by the cells of the zona 
glomerulosa of the adrenal cortex in response to either elevated serum potassium levels or to 
angiotensin II (AngII) acting through its type 1A receptors (AT1ARs), which are endogenously 
expressed in the adrenocortical zona glomerulosa (AZG) cells (5,6). AT1Rs belong to the 
superfamily of 7-transmembrane spanning G-protein coupled receptors (GPCRs), and, upon 
agonist activation, couple to the Gq/11 family of G-proteins (6).  Over the past few years however, 
a number of GPCRs, including the AT1R, have been shown to also signal through G protein-
independent pathways.  The protein scaffolding actions of β-arrestin-1 and -2 (βarr1 and -2, also 
known as arrestins -2 and -3, respectively), originally discovered as terminators of GPCR 
signaling following phosphorylation of these receptors by the GPCR kinases (GRKs), play a 
central role in mediating G protein-independent signal transduction by these receptors (7,8).  
 We recently reported that adrenal GRK2, the major co-factor of βarr action toward 
receptors, is upregulated in HF leading, through its concerted action with βarr1, to increased 
desensitization/down-regulation of α2-adrenoceptors, and this mediates the increased adrenal 
catecholamine output seen in HF (9).  Since adrenal aldosterone production stimulated by AngII 
is increased in HF (1-3), and βarr1 also regulates AT1R signaling (7,8), we hypothesized that 
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adrenal βarr1 might mediate the signaling of AT1R to aldosterone production and secretion.  In 
order to test this in vitro, we used the human AZG cell line H295R, which endogenously 
expresses the AT1R, but not the AT2R (the other AngII receptor type).  Importantly, these cells 
produce and secrete aldosterone in response to AngII stimulation (10,11).  To examine whether 
adrenal βarr1 influences aldosterone turnover in vivo, we used our previously developed 
methodology for adrenal-targeted, adenoviral-mediated gene transfer (9,12) of wild-type full-
length βarr1 in normal rats. We have uncovered a novel signaling pathway mediated by βarr1 
that leads to aldosterone production by the AT1R in AZG cells in vitro, which, importantly, is 
also operative in vivo, since adrenal βarr1 overexpression was found to be capable of increasing 
circulating levels of aldosterone in vivo. 
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Results 
βarr1-mediated AngII-induced aldosterone production in vitro. Since AngII is known to 
promote aldosterone production in AZG cells, we set out to explore a potential role for βarrs in 
this effect.  In H295R cells, treatment with 10 nM AngII leads to a significant induction of 
aldosterone secretion, as expected (Fig. 1A).  Western blotting with an antibody against both βarr 
isoforms in native extracts from these cells revealed that only βarr1 is expressed endogenously in 
significant amounts (Fig. 1B).  Consistent with this, human adrenal glands express βarr1 robustly 
(SI Fig. 1), and importantly, βarr1 co-localizes with the known adrenocortical protein, 
steroidogenic acute regulatory protein (StAR), in human adrenocortical sections (Fig. 1C). 
 Aldosterone synthesis in AZG cells is initiated by the mitochondrial uptake of 
cholesterol, the precursor of all adrenal steroids (10).  Mitochondrial cholesterol uptake is the 
rate-limiting step of this procedure and is catalyzed by the steroid transport protein StAR, whose 
levels are upregulated in response to AngII stimulation (10,13). Consistent with this, we 
observed a large StAR upregulation in H295R cells 6 hrs post-AngII stimulation (Fig. 1B).  
 In order to test whether endogenous βarr1 plays a role in AngII-induced aldosterone 
production/secretion, we transfected H295R cells with the V53D dominant negative βarr1 
mutant (DN βarr1), which prevents βarr1 from interacting with its various intracellular non-
receptor binding partners (14,15). As shown in Fig. 1D, DN βarr1 overexpression led to marked 
inhibition of AngII-induced aldosterone secretion, compared to control empty vector (EV)-
transfected cells.  In addition, the AngII-induced StAR upregulation normally observed in EV-
transfected cells was also absent in DN βarr1-transfected cells (Fig. 1E).  Conversely, 
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transfection of H295R cells with an adenovirus encoding for wild-type βarr1 (Adβarr1) led to 
significantly enhanced AngII-induced aldosterone secretion compared to control AdGFP (Green 
Fluorescent Protein)-transfected cells (Fig. 1F), which was also accompanied by a marked 
enhancement of AngII-induced StAR upregulation (Fig. 1G).  Taken together, these results show 
that βarr1 is necessary for AngII-induced StAR upregulation and subsequent aldosterone 
production in AZG cells in vitro.  
βarr1-mediated AT1R signaling to aldosterone production involves DAG and sustained 
ERK activation.  
To further dissect the signaling pathway of AngII-induced aldosterone production mediated by 
βarr1 in AZG cells, we focused on βarr1-promoted ERK1/2 activation. ERK1/2 play a central 
role in StAR upregulation by means of inducing StAR gene transcription in response to AngII 
stimulation in AZG cells (13).  βarrs have been shown to mediate AT1R signaling to ERKs in 
various heterologous cell systems in vitro (7,8).  Following AngII stimulation for various times, 
we found that βarr1 overexpression does lead to sustained AngII-induced ERK1/2 activation in 
H295R cells, lasting at least 6 hrs and contrary to a more transient ERK1/2 activation by AngII 
in control AdGFP-transfected cells (Figs. 2A & 2B).  Conversely, inhibition of endogenous βarr1 
by DN βarr1 completely abrogates AngII-induced ERK1/2 activation in H295R cells compared 
to EV-transfected cells (Figs. 2A & 2B).  These data indicate that βarr1 promotes a sustained 
AngII-induced ERK1/2 activation, which could underlie the observed βarr1-promoted StAR 
upregulation and aldosterone production in response to AngII in AZG cells. 
 Recently, βarr1 was shown to recruit the diacylglycerol (DAG) kinases (DGKs) to 
activated M1 muscarinic cholinergic receptors, which also couple to Gq-proteins like the AT1Rs, 
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thereby catalyzing the conversion of the Gq-dependent second messenger DAG to phosphatidic 
acid (PA) at the cell membrane (16). PA is a potent ERK cascade activator by means of bringing 
together Ras and Raf1 kinase at the level of the plasma membrane to interact with each other 
(17). Therefore, we hypothesized that this βarr1-mediated mechanism could be at play in AngII-
induced sustained ERK1/2 activation in AZG cells, as well. To test this, we pretreated 
transfected H295R cells with the phospholipase C (PLC) inhibitor U73122 (18) to suppress all 
DAG production before AngII stimulation. In the presence of PLC inhibition, βarr1 
overexpression is unable to induce StAR upregulation or ERK activation in response to AngII 
stimulation, which are also absent in control AdGFP-transfected cells, as expected (Figs. 2D & 
2C, respectively, and quantitation in Figs. 2F & 2E, respectively). Adding the cell-permeable 
DAG analog dioctanoylglycerol (DiC8-DAG) however (19), which circumvents PLC inhibition 
and is a DGK substrate, immediately before applying AngII to the PLC inhibitor-treated cells, 
rescues the ability of βarr1 to mediate StAR upregulation and ERK activation in response to 
AngII, both in βarr1-overexpressing and in control AdGFP-transfected cells (Figs. 2D & 2C, 
respectively, and quantitation in Figs. 2F & 2E, respectively). Importantly, in the presence of 
PLC inhibition, βarr1 is also incapable of promoting AngII-induced aldosterone production in 
H295R cells (Fig. 2G), and this capability is again rescued by the addition of DiC8-DAG (Fig. 
2H). Finally, application of the MEK1 inhibitor PD98059 which abolishes ERK1/2 activation led 
to a complete abrogation of AngII-induced ERK activation and StAR upregulation (Figs. 2D & 
2C, respectively, and quantitation in Figs. 2F & 2E, respectively), as well as of AngII-induced 
aldosterone production (Fig. 2G) both in βarr1-overexpressing and in control AdGFP-transfected 
cells, thus confirming the vital role of ERK1/2 in mediation of AngII-induced aldosterone 
production in AZG cells (13). Taken together, these results indicate that DAG is necessary for 
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βarr1-mediated ERK1/2 activation, StAR upregulation and aldosterone production in AZG cells 
induced by AngII, probably via βarr1-recruited DGK-catalyzed conversion to PA.  
The βarr1-mediated signaling pathway operates independently of G-protein activation.                                                                                                                    
Next, we examined whether this βarr1-mediated signaling pathway of AngII-dependent 
aldosterone production can proceed without the activation of the cognate AT1R G-protein 
pathway. To this end, we took advantage of the well characterized AngII analog [Sar1,Ile4,Ile8]-
AngII (SII), which is a biased AT1R agonist, in that it does not induce the coupling of AT1R to 
G-proteins, but instead induces receptor interaction with βarrs and downstream βarr-mediated 
signaling (20).  As shown in Fig. 3A, SII, at the relatively high concentration of 10µM, is also 
able to induce aldosterone secretion from H295R cells, and this is enhanced in cells 
overexpressing βarr1 (Fig. 3A).  Conversely, transfection with DN βarr1 abolishes SII-induced 
aldosterone secretion (Fig. 3A).  Of note, 1 µM SII treatment could stimulate aldosterone 
secretion only in the presence of βarr1 overexpression (data not shown), consistent with far less 
potency of this compound at stimulating βarrs compared to AngII (21). In addition, 10 µM SII 
treatment results also in ERK1/2 activation (Fig. 3B) and StAR upregulation (Fig. 3C), which are 
again enhanced by βarr1 overexpression and abrogated by DN βarr1 (Figs. 3B & 3C).  Taken 
together, these results indicate that βarr1 is able to mediate AT1R signaling to aldosterone 
production in AZG cells in its own right, i.e. even without concomitant activation of G-proteins 
by the AT1R.  
βarr1 mediates aldosterone production in vivo. Next, we examined whether adrenal βarr1 can 
affect aldosterone production in vivo, as well. Adrenal gland-specific overexpression of βarr1 in 
normal rats via infection with Adβarr1 in vivo led to a significant increase in plasma aldosterone 
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levels compared to control AdGFP rats (536+50 pg/ml vs. 235+40 pg/ml, respectively, n=5, 
p<0.01) (Fig. 4A) at seven days post-in vivo gene delivery. βarr1 was markedly overexpressed in 
the adrenals of Adβarr1 rats (Fig. 4B).  
Since GRK2 is a co-factor of βarr1 activity towards receptors, we also delivered an adenovirus 
carrying GRK2 (AdGRK2) to normal rat adrenal glands.  As shown in Fig. 4A, GRK2 
overexpression resulted in a small but significant increase in plasma aldosterone at 7 days post-
gene delivery compared to control AdGFP-treated rats (322+20 pg/ml, n=5, p<0.05 vs. AdGFP), 
indicating that increased activity/expression of GRK2 in the adrenal gland increases aldosterone 
production, as well.  This is consistent with induced βarr1 acting at the plasma membrane. Fig. 
4B shows the overexpression of the respective transgenes in the adrenals of normal rats.  Of note, 
all transgenes delivered in vivo displayed adrenal-specific overexpression with no ectopic 
expression in any other tissue tested (Ref. 12, and data not shown).  In addition, plasma 
aldosterone values in saline-treated rats were similar to AdGFP-treated rats (Fig. 4A), indicating 





 Over the past few years, a novel role for βarr1 and -2, molecules initially discovered as 
terminators of G protein signaling by GPCRs, has emerged, i.e. that these two proteins, after 
uncoupling the activated receptor from its cognate G-protein, actually serve as signal transducers 
for the receptor in their own right (7,8). However, this novel role of βarrs has thus far been 
demonstrated almost exclusively in heterologous cell systems in vitro.  The present study 
delineates a novel signaling pathway mediated by βarr1, which operates in vitro and in vivo, in a 
specialized cell type/tissue (ZG cells of the adrenal cortex), and which leads to an important 
physiological effect (AngII-induced aldosterone production).  Moreover, this increased 
aldosterone production may then precipitate diseases that are characterized and aggravated by 
enhanced circulating levels of this hormone, such as post-MI HF progression (3,4).  
 Additionally, our data strongly suggest that blocking adrenal βarr1 actions on AT1R 
might serve as a novel therapeutic strategy for lowering aldosterone levels in pathological 
conditions characterized and precipitated by elevated aldosterone levels, one of the most 
important of which is post-MI progression to HF. Testing the effects of adrenal βarr1 inhibition 
in vivo in post-MI HF in order to validate this important receptor regulatory protein as a novel 
therapeutic target in HF will be the focus of our next study.  
           Suppression of aldosterone production at its various sources, the most important of which 
physiologically is the adrenal cortex, is of particular importance, since aldosterone has been 
shown to exert some of its actions (its so-called “non-genomic” actions) by binding other 
molecular targets than the mineralocorticoid receptor (MR), the molecular target that normally 
mediates its cellular actions (2,3). These MR-independent actions are of course unaffected by the 
currently available MR antagonist drugs, such as eplerenone and spironolactone, used in the 
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treatment of HF.  Therefore, curbing aldosterone production at its major source, i.e. the adrenal 
cortex, by inhibiting βarr1 actions, could presumably be more effective therapeutically than 
inhibiting its actions at its receptor level and we are planning to investigate this in an in vivo 
experimental model of HF.  
 The pathway of βarr1-dependent AT1R signaling to aldosterone production appears to be 
initiated by the recruitment of βarr1 to the activated AT1R which scaffolds DGK(s) to the 
activated receptor. This, in turn, leads to conversion of DAG to PA, a membrane phospholipid 
that can directly activate the ERK cascade.  The resulting sustained ERK activation leads to 
activation of StAR gene transcription, thereby causing up-regulation of this cholesterol-
transporting protein. The StAR-facilitated mitochondrial uptake of cholesterol subsequently 
initiates aldosterone synthesis in AZG cells. This signaling pathway is schematically depicted in 
Fig. 5. Of note, StAR is the major regulator of the biosynthesis of all adrenal steroids throughout 
the adrenal cortex (10), not only of aldosterone, therefore βarr1 is very likely to be involved in 
regulation of the synthesis of glucocorticoids and androgens (the other two categories of adrenal 
steroids) by the adrenal cortex, as well.  
 Although AT1R has been shown to result in sustained ERK activation via βarrs, it is the 
βarr2 isoform that has actually been shown to mediate this effect, whereas βarr1 has actually 
been shown to act in the opposite direction, i.e. rather inhibiting AT1R-induced ERK activation 
(22). Recently, it was shown in transfected HEK293 cells that βarr1 only inhibits AT1R signaling 
to ERK by classically desensitizing the receptor (i.e. uncoupling it from the G protein), and βarr2 
instead promotes the G protein-independent signaling of AT1R to ERKs, but this βarr2-mediated 
ERK activation produces no transcriptional effects (23). Our present findings seem to be in 
discordance with these studies. However, it should be emphasized here that these studies were 
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done in transfected heterologous systems, with overexpressed receptors at supra-physiological 
levels, and also with recombinant (not natural) AT1Rs engineered in such a way that they cannot 
couple to any G proteins. Given that signaling from a given GPCR to ERKs can vary widely 
depending on the relative concentrations of receptor, G-proteins, GRKs, and βarrs, as well as on 
the cellular context in general (i.e. cell type and cellular signaling machinery) (8,23), this 
apparent discrepancy can be easily explained.  Additionally, the H295R cells used in the present 
study do not express significant amounts of βarr2 endogenously, so βarr2 is unlikely to be 
involved in AngII-induced aldosterone production, at least in this system (see Figure 1B).  
Nevertheless, it is entirely plausible that βarr2 might have different or even opposite effects on 
the signaling pathway leading from AT1R activation to aldosterone production in other AZG cell 
lines or in vivo, and this is going to be the focus of future studies. 
 βarr-activated ERKs have been shown to be largely retained in the cytosol due to their 
association with receptor-arrestin complexes, and thus not to be able to translocate to the nucleus 
to induce transcriptional effects (22,23). However, βarr1 localizes in the cytoplasm, as well as in 
the nucleus by virtue of possessing a nuclear localization sequence, whereas βarr2 is excluded 
from the nucleus due to a nuclear export sequence present in its molecule (24). In fact, βarr1 
translocates into the nucleus in response to stimulation of the µ-opioid receptor, a Gi/o-coupled 
receptor, wherein it interacts with the p27 and c-Fos promoters and stimulates transcription by 
recruiting histone acetyltransferase p300 and enhancing local histone H4 acetylation (25,26). On 
the other hand, ERK1/2 not only target nuclear transcription factors, but also numerous other 
plasma membrane, cytoplasmic, and cytoskeletal substrates (27), some of which mediate the 
reportedly non-transcriptional effects of βarr-activated ERKs, such as chemotactic T- and B-cell 
migration (28,29). Some other ERK substrates though, such as the Rsk and Mnk protein kinases, 
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can translocate to the nucleus and activate transcription factors, thereby producing the 
transcriptional effects of activated ERK1/2 indirectly (27). Indeed, the cardiac-specific 
overexpression of a G protein-uncoupled mutant AT1R has been reported, which induces 
ERK1/2 activation that promotes a histologically distinct form of cardiac hypertrophy from that 
caused by the wild type receptor, with greater cardiomyocyte hypertrophy and less cardiac 
fibrosis (30). This suggests that ERK1/2 activated independently of G proteins can produce 
transcriptional effects from AT1R activation in vivo, albeit different from the transcriptional 
effects of G-protein-activated ERKs.  In the same vein, βarr1 was very recently shown in 3T3-L1 
adipocytes to mediate ERK activation from the endogenous TNFα receptor (a cytokine receptor) 
through Gq/11-proteins, and this βarr1-mediated ERK activation coupled TNFα receptor 
activation to lipolysis, phosphatidylinositol 3-kinase activation and inflammatory gene 
expression (31). Taken together, all these studies indicate that βarr1-activated ERK1/2 can lead 
to transcriptional effects, which is in complete agreement with our present findings, i.e. that 
βarr1-activated ERK1/2 increases StAR expression and aldosterone synthesis in AZG cells. 
Indeed, βarr1-activated ERK1/2 appears to increase StAR expression in H295R cells 
transcriptionally, via suppression of the early intermediate gene DAX-1 (13), a transcriptional 
repressor of the StAR gene (data not shown). 
            The final important finding of the present study is that SII can completely recapitulate the 
AngII effects on aldosterone production, albeit at significantly lower concentrations, consistent 
with its lower potency at AT1R compared to the physiological full agonist AngII. This finding 
has enormous pharmacological and therapeutic ramifications, since it strongly argues for the 
existence of at least two different active conformations of the AT1R, one of which would lead 
only to βarr1 but not G-protein activation, but which both result in aldosterone production in 
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AZG cells. Therefore, complete blockade of both of these conformations would be warranted in 
order to achieve the most effective suppression of AngII-dependent aldosterone production. To 
our knowledge, the relative efficacy of the currently available AT1R antagonist drugs (the 
sartans) at inhibiting these two signaling pathways emanating from AT1R (i.e. the G protein- and 
the βarr-mediated) has never been tested and is completely unknown and thus will also be the 
focus of our future studies. In fact, there have been several reports of limited efficacy of some 
AT1R antagonists at suppressing aldosterone in HF (32-34), despite their more or less equal 
capability to inhibit G-protein activation by the AT1R. It would thus be interesting to examine 
whether variations in the efficacy of these agents at inhibiting AT1R−βarr coupling could 
account for their reduced efficacy at suppressing aldosterone. Based on the results of the present 
study however, the most effective AT1R antagonist at inhibiting AngII-dependent aldosterone 
production should be an agent that would inhibit both AT1R-G protein and AT1R-βarr1 coupling 
equally well.  
 In conclusion, the present study reports a novel, G protein-independent signaling pathway 
mediated by βarr1 in adrenocortical zona glomerulosa cells that underlies aldosterone production 
in response to AngII in vitro and in vivo. Activity of this pathway appears to regulate adrenal 
aldosterone production, and hence circulating levels of this mineralocorticoid in vivo. Thus, 
adrenal βarr1 activity towards the AT1R might represent a novel therapeutic target for reducing 
plasma aldosterone levels in pathological conditions where this is desirable, including several 




Materials. [Sar1,Ile4,Ile8]-AngII (SII) was a generous gift from Dr. P. Cordopatis (University of 
Patras School of Pharmacy, Patras, Greece). U73122 was from Biomol (Plymouth Meeting, PA, 
USA) and DiC8-DAG from Sigma (Sigma-Aldrich, St Louis, MO, USA). 
In vivo adrenal gene delivery in normal rats. All animal procedures and experiments were 
performed in accordance with the guidelines of the IACUC of Thomas Jefferson University.  
Adrenal-specific in vivo gene delivery was done essentially as described (12), via direct delivery 
of adenovirus in the adrenal glands.   
Construction and purification of adenoviruses. Recombinant adenoviruses that encode GRK2 
(AdGRK2) or rat wild type, full length β-arrestin1 (Adβarr1) were constructed as described 
previously (9). Briefly, transgenes were cloned into shuttle vector pAdTrack-CMV, which 
harbors a CMV-driven green fluorescent protein (GFP), to form the viral constructs by using 
standard cloning protocols. As control adenovirus, empty vector which expressed only GFP 
(AdGFP) was used. The resultant adenoviruses were purified, as described previously, using two 
sequential rounds of CsCl density gradient ultracentrifugation (9).   
H295R cell culture and transfection. H295R cells were purchased from American Type 
Culture Collection (Manassas, VA, USA) and cultured as previously described (35). Transfection 
was performed either with Adβarr1 or AdGFP or with pcDNA3.1 plasmid encoding either for 
the V53D dominant negative βarr1 mutant (14) (DN βarr1, a generous gift of Dr. Lefkowitz, 
Duke University Medical Center, Durham, NC, USA) or just empty pcDNA3.1 vector (EV).  
Plasmid transfections were performed using the Lipofectamine 2000 reagent (Invitrogen, 
Carlsbad, CA, USA). 
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Plasma and in vitro aldosterone secretion measurements. Rat plasma aldosterone levels and 
in vitro aldosterone secretion in the culture medium of H295R cells were determined by EIA 
(Aldosterone EIA kit, ALPCO Diagnostics, Salem, NH, USA), as described (34).  
Western blotting. Western blots to assess protein levels of StAR (sc-25806), GRK2 (sc-562; 
Santa Cruz Biotechnology, Santa Cruz, CA, USA), phospho-ERK1/2 (#9106), total ERK1/2 
(#4696), and total ERK2 (#9108; Cell Signaling Technology, Danvers, MA), βarr1 (A1CT 
antibody, Ref. 16, a generous gift of Dr. Lefkowitz, Duke University Medical Center, Durham, 
NC, USA), and GAPDH (MAB374; Chemicon, Temecula, CA, USA) were done using protein 
extracts from rat adrenal glands or in H295R cell extracts, as described previously (9). 
Visualization of western blot signals was performed with Alexa Fluor 680– (Molecular Probes) 
or IRDye 800CW–coupled (Rockland Inc.) secondary antibodies on a LI-COR infrared imager 
(Odyssey). 
Co-immunofluorescence. Immunofluorescence imaging of human adrenal cross-sections was 
carried out as described previously (9). Briefly, human adrenal cross-sections were fixed, 
permeabilized and labeled with rabbit polyclonal anti-StAR (sc-25806) and goat anti-βarr1 (sc-
9182; Santa Cruz Biotechnology, Santa Cruz, CA, USA) antibodies, followed by the 
corresponding Alexa Fluor 594 anti-goat (red) and Alexa Fluor 568 anti-rabbit (green) secondary 
antibodies (Molecular Probes, Eugene, OR, USA). Confocal images were obtained using a ×40 
objective on a Leica Microsystems TCS SP laser scanning confocal microscope.   
Statistical analyses. Data are generally expressed as mean ± SEM.  Unpaired 2-tailed Student’s t 
test and one- or two-way ANOVA with Bonferroni test were generally performed for statistical 
comparisons, unless otherwise indicated.  For all tests, a p value of <0.05 was generally 
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Fig. 1. Involvement of βarr1 in AngII-induced aldosterone production and secretion in H295R 
cells. (A) Aldosterone secretion in response to 10 nM AngII treatment (AngII) or vehicle 
(Control) for 6 hrs in H295R cells. *, p<0.05, n=4 independent experiments. (B) Top: 
Representative immunoblots for endogenous βarrs and StAR in protein extracts from vehicle- 
(Cont.) and AngII-treated (AngII) H295R cells, including blots for GAPDH as loading control. A 
lane run with extract from HEK293 cells (HEK), as a positive control for both βarr isoforms, is 
also shown. Bottom: Densitometric analysis of StAR protein expression normalized to GAPDH 
levels. *, p<0.05, n=4 independent experiments. (C) Co-immunofluorescence in sections of 
human adrenal glands using antibodies specific for StAR (green) and βarr1 (red), showing co-
localization of the two fluorescent signals (yellow), which indicates endogenous expression of 
βarr1 in human adrenocortical cells. Scale bar: 100 µm. (D) Aldosterone secretion in H295R 
cells transfected with empty vector (EV) or with a plasmid encoding for the V53D dominant 
negative βarr1 (DN βarr1), and stimulated with 10 nM AngII or vehicle for 6 hrs. *, p<0.05, n=5 
independent experiments. (E) Western blotting for StAR in these cells at the end of the indicated 
treatments. Blots for βarr1 to confirm DN βarr1 overexpression are also shown, along with 
GAPDH as loading control. On top: representative blots, on bottom: densitometric quantification 
of 5 independent experiments. *, p<0.05, n=5. (F) Aldosterone secretion in H295R cells 
transfected with Adβarr1 or AdGFP, and stimulated with 10 nM AngII or vehicle for 6 hrs. *, 
p<0.05, n=5 independent experiments. (G) Western blotting for StAR. Representative blots 
confirming the overexpression of βarr1, along with GAPDH as loading control, are shown on 




Fig. 2. βarr1-mediated AngII signaling to aldosterone production in H295R cells. (A) Western 
blotting for phospho-ERK1/2 and for total ERK2 in extracts from transfected H295R cells after 
10 nM AngII stimulation for the indicated times. Representative blots of 3 independent 
experiments are shown, including blots for βarr1 to confirm the overexpression of the transfected 
proteins. (B) Densitometric quantification of the 3 independent experiments performed in (A). *, 
p<0.05, vs. AdGFP, **, p<0.05, vs. DN βarr1. (C,D) Western blotting in control AdGFP- or in 
Adβarr1-transfected H295R cells treated with vehicle or 10 nM AngII for 6 hrs following 
pretreatment with 10 µM U73122, 10 µM U73122 plus 10 µM DiC8-DAG, or 50 µM PD98059. 
Representative blots of 3 independent experiments for each cell line are shown, including blots 
for endogenous βarr1 and for total ERK1/2 and GAPDH as loading controls. (E,F) AngII-
induced ERK phosphorylation and StAR upregulation as densitometrically quantitated in the 3 
independent experiments performed in (C) and (D), respectively. Values are expressed as % of 
the AngII response of cells not pretreated with any agent (No Inhibitor). *, p<0.05, vs. No 
Inhibitor, n=3. (G) Aldosterone secretion in Adβarr1- or AdGFP-transfected cells pretreated with 
10 µM U73122 or µM PD98059, followed by 10 nM AngII or vehicle stimulation for 6 hrs. No 
significant differences at p=0.05, n=3 independent experiments. (H) Aldosterone secretion in 
Adβarr1- or AdGFP-transfected cells pretreated with 10 µM U73122 plus 10 µM DiC8-DAG, 
followed by 10 nM AngII or vehicle stimulation for 6 hrs. *, p<0.05, vs. –AngII, n=3 
independent experiments. 
 
Fig. 3. SII-induced aldosterone production and secretion in H295R cells. (A) Aldosterone 
secretion in transfected H295R cells stimulated with 10 µM SII or vehicle for 6 hrs. Data are 
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shown as the % induction over vehicle (basal) levels of aldosterone secretion.  *, p<0.05, vs. 
AdGFP or EV, n=5 independent determinations/treatment. (B) Western blotting for phospho-
ERK1/2 and for total ERK2 after 10 µM SII or vehicle. Representative blots of 3 independent 
experiments are shown on top and the % SII-induced ERK activation (over basal), as derived by 
densitometric quantification, is shown on bottom. *, p<0.05, n=3 independent experiments. (C) 
Western blotting for StAR after 10 µM SII or vehicle. Representative blots of 3 independent 
experiments are shown on top, including blots for βarr1 to confirm the overexpression of the 
respective constructs and for GAPDH as loading control, and the % SII-induced StAR induction 
(over basal), as derived by densitometric quantification, is shown on bottom. *, p<0.05, n=3 
independent experiments. 
 
Fig. 4. In vivo adrenal-targeted βarr1 overexpression and aldosterone production in normal rats. 
(A) Plasma aldosterone levels in AdGFP-, AdGRK2-, or Adβarr1-treated, plus in saline-treated 
(Saline), normal rats at 7 days post-in vivo gene transfer. *, p<0.05, **, p<0.01, vs. AdGFP or 
Saline, n=5 rats/group. (B) Representative western blots in protein extracts from adrenal glands 
from these rats, confirming the overexpression of the respective transgenes. GAPDH is also 
shown as loading control. 
Fig. 5. Schematic representation of the signaling pathway of AngII-induced aldosterone 
production mediated by βarr1. See text for details. ZG: Zona Glomerulosa, AngII: Angiotensin 
II, AT1R: AngII receptor type I, βarr1: beta-arrestin 1 (arrestin-2), Gq: Gq protein, PLC: 
Phospholipase C, PIP2: Phosphatidylinositol 4`,5`-bisphosphate, DAG: Diacylglycerol, IP3: 
Inositol 1`,4`,5`- trisphosphate, DGK: Diacylglycerol kinase, PA: Phosphatidic acid, pERK: 
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phospho-Extracellular Signal-Regulated Kinase, MEK1: MAPK-ERK Kinase-1, StAR: 
Steroidogenic Acute Regulatory protein. 
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